Vaxcyte, Inc. (PCVX) SEC Filings & Earnings Calls

Dilution risk from equity offering and potential conversion of notes

“Pre-funded warrants and convertible notes may dilute existing shareholders upon conversion or exercise.”

Regulatory risk remains; FDA review of BLA may require additional data.

“BLA submission planned for first half 2028; FDA review process pending.”

Clinical trial risk remains; OPUS-1 data readout is binary event.

“Topline data from VAX-31 OPUS-1 expected by end of October 2026.”

No approved products or revenue

“We do not have any products approved for sale and have not generated any revenue from product sales.” · word for word

Significant operating losses and accumulated deficit

“We have incurred significant net losses since inception and anticipate that we will continue to incur substantial net losses for the foreseeable future.” · word for word

Dependence on single-source manufacturers

“We rely on third-party contract manufacturers to manufacture preclinical and clinical trial product materials and supplies for our needs.” · word for word

Clinical trial and regulatory approval uncertainty

“Our vaccine candidates are in clinical or preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability.” · word for word

Intense competition from larger players

“Our primary competitors have significantly greater resources and experience than we do, which may make it difficult for us to successfully develop and commercialize our vaccine candidates.” · word for word

Clinical trial failure risk for VAX-31 and VAX-A1

“Company is pre-revenue; pipeline success depends on Phase 3 and Phase 1 readouts”

No approved products or revenue

“We do not have any products approved for sale and have not generated any revenue from product sales.” · word for word

Significant net losses and accumulated deficit

“Our net losses were $766.6 million and $463.9 million for the years ended December 31, 2025 and 2024, respectively, and $320.6 million and $140.7 million for the three months ended March 31, 2026 and 2025, respectively.” · word for word

Clinical trial and regulatory approval risk

“We may encounter substantial delays in our clinical trials or may not be able to conduct our trials on the timelines we expect.” · word for word

Manufacturing dependency and capacity risk

“The cumulative impact of the time required to make adjustments to our processes led to a delay of our drug substance manufacturing campaign due to scheduling conflicts and capacity constraints at Lonza.” · word for word

Intense competition from larger players

“Our primary competitors have significantly greater resources and experience than we do, which may make it difficult for us to successfully develop and commercialize our vaccine candidates” · word for word

Clinical-stage biotech with no approved products; significant reliance on VAX-31 Phase 3 data readouts.

“Topline data from OPUS-1 expected in Q4 2026; OPUS-2 and OPUS-3 in H1 2027”

Clinical Development Risk

“Our vaccine candidates are in clinical or preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability.” · word for word

Novel Technology Risk

“Our approach to the discovery and development of our vaccine candidates is based on novel technologies that are unproven, which may expose us to unforeseen risks, require us to modify processes, and make it difficult to predict the time and cost of vaccine candidate development and the timing to apply for and obtain regulatory approvals.” · word for word

Funding Risk

“We will require substantial additional funding to finance our operations, which may not be available to us on acceptable terms, or at all. If we are unable to raise additional capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.” · word for word

Competition Risk

“Our primary competitors have significantly greater resources and experience than we do, which may make it difficult for us to successfully develop and commercialize our vaccine candidates, or may result in others discovering, developing or commercializing products before or more successfully than us.” · word for word

Clinical-stage biotech with no approved products; significant R&D expenses and reliance on trial success.

“Clinical-stage vaccine innovation company... VAX-31 Phase 3 program ongoing; no revenue from product sales.”

Potential dilution from future ATM sales; compensation of 3% of gross proceeds to placement agent.

“Placement Agent will be entitled to compensation of up to 3.00% of the gross proceeds from the sale of the Shares.” · word for word

Dilution from equity offering.

“issuance and sale of 11,000,000 shares of its common stock”

Increased severance obligations may raise cash outflow in event of termination or change in control, but no immediate financial risk.

“Severance multipliers increased for CEO and other executives; effective Dec 31, 2025.”

Clinical development risk

“Our vaccine candidates are in clinical or preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability.” · word for word

Manufacturing risk

“We and our contract manufacturers may face difficulty satisfying CMC requirements imposed by the FDA and comparable foreign regulatory authorities.” · word for word

Competitive risk

“Our primary competitors have significantly greater resources and experience than we do, which may make it difficult for us to successfully develop and commercialize our vaccine candidates.” · word for word

Regulatory approval risk

“We cannot guarantee that we will ever obtain regulatory approval for any of our vaccine candidates.” · word for word

Clinical-stage company with no approved products; pipeline risk.

“clinical-stage vaccine innovation company” · word for word